Innovative COPD therapies to preserve patient lung health
Our dNerva® Lung Denervation System is a catheter-based system used to treat overactive airways that may help to reduce the frequency and severity of Chronic Obstructive Lung Disease (COPD) exacerbations.
Targeted Lung Denervation
Procedure Highlights
One-time, outpatient procedure
Whole lung treatment
“Always on” bronchodilation
Lower risk of COPD exacerbations
Our Therapy Impact on COPD Patient Outcomes
After 2 Years 2
- 62% Lower Risk of Severe Exacerbation in COPD Patients
After 3 Years 21,22
Observed Clinical Stability:
- Stable quality of life after treatment
- Stable lung function after treatment
- Positive long-term safety profile
COPD Statistics
Global Burden of COPD
16M
According to the CDC, COPD affects more than 16 million Americans.
150%
increase in disease-related hospitalizations over the next 15 years in developed countries.23
$72B
COPD is responsible for $72B in annual direct healthcare expense with hospitalizations being the biggest driver of those costs.6,7,8,9
14x
COPD patients from the UK showed a 14X greater risk of death in the year following a severe exacerbation.18
dNerva Lung Denervation System
The dNerva Lung Denervation System is a catheter-based system used to complete a one-time, bronchoscopic procedure to disrupt nerve input to and from the lungs to reduce the clinical consequences of neural hyperactivity.
Current Therapies Aren’t Always Enough
Half of Patients on Optimal Medical Therapy Continue to Exacerbate
Prescribed medications are an integral component of managing COPD exacerbations, but optimal drug therapy is not always effective at preventing these exacerbations.10,11
COPD Exacerbations are the Problem.
Be a Part of the Solution.
The AIRFLOW-3 Clinical Trial is the first interventional COPD trial targeting exacerbation risk reduction in patients on optimal drug therapy.